Printer Friendly

IMMULOGIC VICE PRESIDENT JANET C. BUSH WILL RESIGN AUG. 31, 1992

 IMMULOGIC VICE PRESIDENT JANET C. BUSH WILL RESIGN AUG. 31, 1992
 CAMBRIDGE, Mass., May 22 /PRNewswire/ -- ImmuLogic Pharmaceutical Corporation (NASDAQ: IMUL) announced at its annual stockholders' meeting that Janet C. Bush, the company's vice president, finance and administration, treasurer and secretary, would be resigning her responsibilities effective Aug. 31, 1992.
 "Ms. Bush has made a substantial and important contribution to ImmuLogic," said Richard Bagley, president and chief executive officer. "She has informed us that she will be leaving the company to pursue interests in the field of education, and we wish her every success. She will remain with ImmuLogic with her current responsibilities for the next several months while a successor is recruited."
 ImmuLogic is developing products to treat allergies and autoimmune diseases. The company's technical approach is based upon proprietary discoveries and an advanced understanding of the molecular events controlling the human immune system. ImmuLogic is developing the ALLERVAX(tm) family of allergy therapeutics under a joint commercialization with Marion Merrell Dow Inc., and the company is collaborating with Merck & Co., Inc. to develop treatments for Type 1 diabetes and rheumatoid arthritis.
 -0- 5/22/92
 /CONTACT: Richard E. Bagley, president and chief executive officer, of ImmuLogic, 617-494-0060/
 (IMUL) CO: ImmuLogic, Pharmaceutical Corporation ST: Massachusetts IN: MTC SU: PER


TM -- NE003 -- 3182 05/22/92 09:11 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 22, 1992
Words:219
Previous Article:PARAMAX AWARDED $37 MILLION U.S. ARMY CONTRACT
Next Article:"WILD SWANS" WINS 1992 NCR BOOK AWARD Most Valuable Single Book Prize in United Kingdom
Topics:


Related Articles
JESS L. BELSER RESIGNS FROM IMMULOGIC BOARD OF DIRECTORS
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
IMMULOGIC APPOINTS SENIOR DIRECTOR, REGULATORY AFFAIRS
IMMULOGIC ANNOUNCES PUBLIC OFFERING OF 2 MILLION SHARES OF COMMON STOCK AT $22.75 PER SHARE
IMMULOGIC REPORTS FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
IMMULOGIC REPORTS SECOND QUARTER RESULTS
IMMULOGIC REPORTS SECOND QUARTER RESULTS
FOUNTAIN ANNOUNCES COMPLETION OF MANAGEMENT REORGANIZATION; DR. FOUNTAIN TO REJOIN THE COMPANY
BIOGEN ANNOUNCES RESIGNATION OF DR. ROBERT J. GERETY, VICE PRESIDENT -DEVELOPMENT OPERATIONS
Dyax Corp. Names Shirish Hirani Vice President of Program Management, Research Division

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters